Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Enigma Diagnostics Taps Tecan to Make and Market Forthcoming POC Molecular Dx Platform

Enigma Diagnostics Taps Tecan to Make and Market Forthcoming POC Molecular Dx Platform

Feb 11, 2010
Premium

This story was originally published on Feb. 9.

By Ben Butkus

Enigma Diagnostics has taken an important step toward commercializing its PCR-based, point-of-care molecular diagnostic platform by inking a global manufacturing and supply agreement with Tecan.

Enigma, based in Oxford, UK, said that it struck the alliance with Tecan in anticipation of a fourth-quarter commercial launch of its platform for point-of-care influenza diagnostic tests in Europe in partnership with GlaxoSmithKline.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Swabs for Science of Spread

A study of families explores how children transmit SARS-CoV-2, according to the Associated Press.

Genome of the Murder Hornet

US Agricultural Research Service scientists have sequenced the genome of the Asian giant hornet.

In a Pool Together

According to the Economist, pooled testing for COVID-19 could help alleviate strains on testing labs.

Science Presents Paper on Computational Method to Predict IBD Patient Response to Therapy

In Science this week: MIT researchers outline approach dubbed translatable components regression to predict treatment response among IBD patients.

Aug
18
Featured Webinar

COVID-19 Wastewater-Based Epidemiology: Methods and Insights for SARS-CoV-2 Community Surveillance

Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Featured Webinar

Case Study: An IVD Manufacturer’s Experience Building a Complete Sample-to-Result Workflow

Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Featured Webinar

Liquid Biopsy-based Molecular Risk Stratification of ALK-mutated Lung Cancer Patients

Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

What's Popular?

In PCR

  1. SARS-CoV-2 Study Documents Viral Dynamics in Young Adults With or Without Symptoms

  2. Genedrive, Beckman Coulter Life Sciences Partner on Automated PCR Testing for SARS-CoV-2

  3. Fulgent Genetics Touts Returns on COVID-19 Testing Investment

    Premium

  4. Becton Dickinson Fiscal Q3 Revenues Drop 11 Percent

  5. Genetron Health Posts 40 Percent Jump in Q2 Revenues

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.